AMRIF focuses on developing safe and well tolerated treatments for chronic inflammatory diseases.

AMRIF is a spin-off company of Alloksys Life Sciences. Leveraging on the RESCAP® platform, we develop therapies for chronic diseases with an underlying problem of systemic inflammation. Our near term focus is on arthritis and diabetic complications.

AMRIF’s human recombinant therapeutic protein hRESCAP has completed a Ph l clinical study.